CA2093946A1 - Methanediphosphonic acid formulations with ion exchangers - Google Patents

Methanediphosphonic acid formulations with ion exchangers

Info

Publication number
CA2093946A1
CA2093946A1 CA002093946A CA2093946A CA2093946A1 CA 2093946 A1 CA2093946 A1 CA 2093946A1 CA 002093946 A CA002093946 A CA 002093946A CA 2093946 A CA2093946 A CA 2093946A CA 2093946 A1 CA2093946 A1 CA 2093946A1
Authority
CA
Canada
Prior art keywords
ion exchangers
disodium
acid formulations
dosage form
methanediphosphonic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002093946A
Other languages
French (fr)
Other versions
CA2093946C (en
Inventor
Satish Chandra Khanna
Jonathan Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of CA2093946A1 publication Critical patent/CA2093946A1/en
Application granted granted Critical
Publication of CA2093946C publication Critical patent/CA2093946C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Abstract

The invention relates to a novel advantageous oral dosage form for methanediphosphonates, especially the active ingredient disodium pamidronate. A preferred dosage form comprises:
a) disodium-3-amino-1-hydroxypropane-1,1-diphosphonate (disodium pamidronate), b) a cationic macroporous ion exchange resin based on a styrene/divinylbenzene copolymer having an exchangeable aminophosphonate group and, where appropriate, c) further pharmaceutically acceptable excipients.
The ingredients can be processed to form tablets, dragées, capsules etc..
CA002093946A 1992-04-15 1993-04-13 Methanediphosphonic acid formulations with ion exchangers Expired - Fee Related CA2093946C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH1247/92-5 1992-04-15
CH124792 1992-04-15

Publications (2)

Publication Number Publication Date
CA2093946A1 true CA2093946A1 (en) 1993-10-16
CA2093946C CA2093946C (en) 2005-07-05

Family

ID=4205927

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002093946A Expired - Fee Related CA2093946C (en) 1992-04-15 1993-04-13 Methanediphosphonic acid formulations with ion exchangers

Country Status (20)

Country Link
US (1) US5344825A (en)
EP (1) EP0566535B1 (en)
JP (1) JP3970941B2 (en)
KR (1) KR100307786B1 (en)
AT (1) ATE183096T1 (en)
AU (1) AU665814B2 (en)
CA (1) CA2093946C (en)
DE (1) DE59309727D1 (en)
DK (1) DK0566535T3 (en)
ES (1) ES2137241T3 (en)
FI (1) FI110920B (en)
GR (1) GR3031645T3 (en)
HU (1) HU219022B (en)
IL (1) IL105382A (en)
MX (1) MX9302151A (en)
NO (1) NO306978B1 (en)
NZ (1) NZ247398A (en)
PH (1) PH30733A (en)
TW (1) TW237386B (en)
ZA (1) ZA932613B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
US5591730A (en) * 1993-10-12 1997-01-07 The Regents Of The University Of California Inhibition of urinary calculi growth
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US20010007863A1 (en) 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
DE19615812A1 (en) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmaceutical preparation containing diphosphonic acids for oral administration
DE19719680A1 (en) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Use of diphosphonic acids for the preventive treatment of long-term consequences of bladder enlargement or replacement
DK0989848T3 (en) * 1997-06-11 2005-01-17 Procter & Gamble Film-coated tablet for improved upper gastrointestinal tract safety
FI104901B (en) 1997-10-20 2000-04-28 Leiras Oy New methylene bisphosphonic acid derivatives
US6160165A (en) * 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
US6794536B1 (en) 1998-12-10 2004-09-21 Aesqen, Inc. Method for preparation of disodium pamidronate
SE9901272D0 (en) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
ATE297740T1 (en) * 2001-01-23 2005-07-15 Gador Sa BISPHOSPHONATE-CONTAINING COMPOSITIONS FOR PREVENTING AND/OR CUREING METABOLIC BONE DISEASES, METHOD FOR THE PRODUCTION AND USE OF THESE COMPOSITIONS
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
JP4142356B2 (en) 2001-07-05 2008-09-03 オイクロ ヨーロピアン コントラクト リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト PP2C substrate
US20030099711A1 (en) * 2001-08-29 2003-05-29 David Meadows Sustained release preparations
AU2002360619B2 (en) * 2001-12-21 2006-10-05 Allergan Pharmaceuticals International Limited Method for the treatment of bone disorders
PL399493A1 (en) 2002-05-10 2012-11-05 F. Hoffmann-La Roche Ag Bisphosphonic acids for the treatment and prevention of osteoporosis
JP2004018524A (en) * 2002-06-13 2004-01-22 Eucro European Contract Research Gmbh & Co Kg Method for treating arteriosclerosis
EP1396263A1 (en) * 2002-08-09 2004-03-10 Warner-Lambert Company Film coating for tablets and caplets
US20040043072A1 (en) * 2002-09-04 2004-03-04 Will Joanne Patricia Alleviation of upper gastrointestinal irritation
ES2530791T3 (en) * 2002-12-20 2015-03-05 Hoffmann La Roche Ibandronate high dose formulation
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
JP4896480B2 (en) * 2004-10-01 2012-03-14 第一三共ヘルスケア株式会社 Particulate composition of anion exchange resin
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
EP3691646A4 (en) * 2017-10-02 2021-06-30 Board of Regents, The University of Texas System Inhalable composition of clofazimine and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2130794C3 (en) 1971-06-22 1974-07-11 Joh. A. Benckiser Gmbh, 6700 Ludwigshafen Process for the preparation of l-hydroxy-S-aminopropane-ljl-diphosphonic acid
DE2405254C2 (en) 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Use of 3-amino-1-hydroxypropane-1, 1-diphosphonic acid or its water-soluble salts for influencing calcium metabolic disorders in the human or animal body
JPS57177012A (en) * 1981-04-23 1982-10-30 Sumitomo Chem Co Ltd Preparation of chelate resin
IT1201087B (en) * 1982-04-15 1989-01-27 Gentili Ist Spa PHARMACOLOGICALLY ACTIVE BIPPHOSPHONES, PROCEDURE FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS
US4639338A (en) 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
US5057505A (en) * 1986-11-21 1991-10-15 Ciba-Geigy Corporation Substituted aminomethanediphosphonic acids and use in medicaments
EP0274346B1 (en) * 1986-11-21 1991-03-06 Ciba-Geigy Ag Substituted aminomethane-diphosphonic acids
DE3822650A1 (en) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
MX21452A (en) * 1989-07-07 1994-01-31 Ciba Geigy Ag PHARMACEUTICAL PREPARATIONS THAT ARE TOPICALLY ADMINISTERED.
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate

Also Published As

Publication number Publication date
ATE183096T1 (en) 1999-08-15
ES2137241T3 (en) 1999-12-16
DK0566535T3 (en) 2000-03-06
HU9301088D0 (en) 1993-06-28
EP0566535A1 (en) 1993-10-20
FI931633A (en) 1993-10-16
JP3970941B2 (en) 2007-09-05
HUT63766A (en) 1993-10-28
JPH069408A (en) 1994-01-18
AU3696193A (en) 1993-10-21
TW237386B (en) 1995-01-01
NO306978B1 (en) 2000-01-24
US5344825A (en) 1994-09-06
IL105382A0 (en) 1993-08-18
CA2093946C (en) 2005-07-05
NO931367L (en) 1993-10-18
PH30733A (en) 1997-10-17
ZA932613B (en) 1993-10-26
MX9302151A (en) 1993-10-01
DE59309727D1 (en) 1999-09-16
NO931367D0 (en) 1993-04-14
NZ247398A (en) 1995-07-26
EP0566535B1 (en) 1999-08-11
GR3031645T3 (en) 2000-02-29
KR100307786B1 (en) 2001-11-30
HU219022B (en) 2001-04-28
FI931633A0 (en) 1993-04-08
KR940005268A (en) 1994-03-21
IL105382A (en) 1998-06-15
AU665814B2 (en) 1996-01-18
FI110920B (en) 2003-04-30

Similar Documents

Publication Publication Date Title
CA2093946A1 (en) Methanediphosphonic acid formulations with ion exchangers
CA2123160A1 (en) Controlled release formulation
CA2131350A1 (en) Sustained release drug formulation containing a tramadol salt
CA2014889A1 (en) Intra-rectal pharmaceutical foam compositions
AU3258889A (en) Pharmaceutical composition for oral administration, based on a diphosphonic acid derivative
EP0715857A3 (en) Orally applicable pharmaceutical composition containing a water-soluble amino acid as a disintegration accelerator
CA2039053A1 (en) Material for adsorbing pyrogen
ZA881681B (en) Hypocholesterolaemic gel formulation containing a pharmaceutically acceptable non-digestible anion exchange resin
HUT50334A (en) Process for producing arylpiperazinyl-alkilenephenyl-p-heterocycluc compounds, pharmaceutically acceptable acid addition salts thereof and pharmaceutical compositions comprising the compounds as active ingredient
CA2138945A1 (en) Concentrated Aqueous Liquid Detergent Compositions Comprising Polyvinylpyrrolidone and a Terephthalate-Based Soil Release Polymer
CA2311024A1 (en) Pharmaceutical composition for oral administration of chelating agents
AU1888488A (en) Substituted benzimidazoles, a process for the preparation thereof, pharmaceutical formulations containing them, and theuse thereof
AU2080695A (en) Pharmaceutical inhalation compositions containing a solid active ingredient
HUT59316A (en) Process for producing solid, orally administrable dosage forms comprising iphosphamide as active ingredient
AU1039097A (en) A solution for oral administration containing ici 182,780
EP0419890A3 (en) Stable pharmaceutical formulations for antineoplastic compounds having more than one ethyleneimine group, and method
AUPM814994A0 (en) Codeine-containing formulations
IL64755A (en) 1-(2-(4,5,10,11-tetrahydro-1h-dibenzo(a,d)cyclohepten-5-yl)-ethyl)pyrrolidine and pharmaceutically acceptable acid addition salts thereof,their preparation and pharmaceutical compositions containing them
IL85632A (en) Hypocholesterolaemic gel formulation containing a pharmaceutically acceptable non-digestible anion exchange resin
Kuzmin et al. Pharmacokinetics of zixorine administered in single and multiple doses.
Ellsworth et al. Tolerance to two different forms of oral erythromycin.
Ferrari et al. Eosinophilia associated with glaphenin.
AU2400792A (en) Oxazaphosphorines useful as antitumor agents, a process for the preparation thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed